CY1118413T1 - Κρυσταλλικη μορφη πεμιρολαστης - Google Patents

Κρυσταλλικη μορφη πεμιρολαστης

Info

Publication number
CY1118413T1
CY1118413T1 CY20171100039T CY171100039T CY1118413T1 CY 1118413 T1 CY1118413 T1 CY 1118413T1 CY 20171100039 T CY20171100039 T CY 20171100039T CY 171100039 T CY171100039 T CY 171100039T CY 1118413 T1 CY1118413 T1 CY 1118413T1
Authority
CY
Cyprus
Prior art keywords
cooker
crystal former
former
crystal
pamirolast
Prior art date
Application number
CY20171100039T
Other languages
Greek (el)
English (en)
Inventor
Anett Perlberg
Martin Viertelhaus
Ulrika Rosenström
Karol Horvath
Original Assignee
Rspr Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rspr Pharma Ab filed Critical Rspr Pharma Ab
Publication of CY1118413T1 publication Critical patent/CY1118413T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
CY20171100039T 2009-06-16 2017-01-11 Κρυσταλλικη μορφη πεμιρολαστης CY1118413T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18735509P 2009-06-16 2009-06-16
US18734809P 2009-06-16 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (1)

Publication Number Publication Date
CY1118413T1 true CY1118413T1 (el) 2017-06-28

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100039T CY1118413T1 (el) 2009-06-16 2017-01-11 Κρυσταλλικη μορφη πεμιρολαστης

Country Status (31)

Country Link
US (3) US20120157415A1 (enExample)
EP (2) EP3141549A1 (enExample)
JP (2) JP5722317B2 (enExample)
KR (2) KR20170049645A (enExample)
CN (1) CN102596202B (enExample)
AR (1) AR077915A1 (enExample)
AU (1) AU2010261540B2 (enExample)
BR (1) BRPI1015559A2 (enExample)
CA (1) CA2765408A1 (enExample)
CY (1) CY1118413T1 (enExample)
DK (1) DK2443120T3 (enExample)
EA (1) EA025865B1 (enExample)
ES (1) ES2613059T3 (enExample)
HR (1) HRP20170023T1 (enExample)
HU (1) HUE032978T2 (enExample)
IL (1) IL216670A (enExample)
LT (1) LT2443120T (enExample)
ME (1) ME02685B (enExample)
MX (1) MX2011013676A (enExample)
NZ (1) NZ596747A (enExample)
PL (1) PL2443120T3 (enExample)
PT (1) PT2443120T (enExample)
RS (1) RS55558B1 (enExample)
SA (1) SA114350792B1 (enExample)
SG (1) SG176295A1 (enExample)
SI (1) SI2443120T1 (enExample)
SM (2) SMT201700085T1 (enExample)
TW (1) TWI504599B (enExample)
UY (1) UY32711A (enExample)
WO (2) WO2010146341A2 (enExample)
ZA (1) ZA201109045B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005513A (es) * 2009-11-13 2012-06-19 Cardoz Ab Pemirolast para el tratamiento de inflamacion sistemica de bajo grado.
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
WO2016063085A1 (en) 2014-10-23 2016-04-28 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
CN110267661B (zh) * 2016-10-03 2021-08-03 布利本迅药业(上海)有限公司 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド[1,2―a]ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
HUE029336T2 (en) 2005-09-16 2017-02-28 Daiichi Sankyo Co Ltd For the preparation of an optically active diamine derivative and process
CN101610765A (zh) * 2006-12-18 2009-12-23 卡多兹公司 用于治疗炎症的新组合物
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
LT2443120T (lt) 2017-02-10
WO2010146348A3 (en) 2011-03-03
PT2443120T (pt) 2017-02-08
AU2010261540A1 (en) 2012-01-19
CA2765408A1 (en) 2010-12-23
CN102596202A (zh) 2012-07-18
US9006431B2 (en) 2015-04-14
EP2443120B1 (en) 2016-11-02
MX2011013676A (es) 2012-02-08
ZA201109045B (en) 2013-05-29
TWI504599B (zh) 2015-10-21
US20170202839A1 (en) 2017-07-20
SG176295A1 (en) 2012-01-30
KR20120032530A (ko) 2012-04-05
EP2443120A2 (en) 2012-04-25
EP3141549A1 (en) 2017-03-15
ES2613059T3 (es) 2017-05-22
UY32711A (es) 2011-01-31
WO2010146348A9 (en) 2012-05-03
PL2443120T3 (pl) 2017-04-28
WO2010146341A2 (en) 2010-12-23
SMT201700085T1 (it) 2017-03-08
IL216670A0 (en) 2012-02-29
AU2010261540B2 (en) 2016-04-14
AR077915A1 (es) 2011-10-05
WO2010146348A2 (en) 2010-12-23
DK2443120T3 (en) 2017-01-09
NZ596747A (en) 2014-01-31
US20120157415A1 (en) 2012-06-21
HRP20170023T1 (hr) 2017-03-10
JP2012530118A (ja) 2012-11-29
IL216670A (en) 2017-02-28
EA201200017A1 (ru) 2013-10-30
EA025865B1 (ru) 2017-02-28
HUE032978T2 (hu) 2017-11-28
SI2443120T1 (sl) 2017-04-26
TW201100422A (en) 2011-01-01
ME02685B (me) 2017-06-20
RS55558B1 (sr) 2017-05-31
BRPI1015559A2 (pt) 2016-04-26
SA114350792B1 (ar) 2015-11-10
CN102596202B (zh) 2015-01-21
AU2010261540A2 (en) 2012-01-19
SMT201700085B (it) 2017-03-08
US20140329839A1 (en) 2014-11-06
KR20170049645A (ko) 2017-05-10
JP5722317B2 (ja) 2015-05-20
WO2010146341A3 (en) 2011-03-03
JP2015120750A (ja) 2015-07-02

Similar Documents

Publication Publication Date Title
CY1118413T1 (el) Κρυσταλλικη μορφη πεμιρολαστης
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
PL3512252T3 (pl) Schematy przekazywania komunikatów o awarii
DK2534173T3 (da) Manipulerede spaltnings-halvdomæner
BRPI1010795A2 (pt) compostos antivirais
CR20130045A (es) Compuestos terapéuticos
BR112013028512A2 (pt) cápsula
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
EP2650593A4 (en) LIGHT SOURCE
EP2490698A4 (en) MODULATION OF AXONES DEGENERATION
HUE055375T2 (hu) Fluorszulfonil-imid alkálifémsója
PL2742051T3 (pl) Amorficzna postać soli sodowej dolutegrawiru
BR112013023523A2 (pt) intensificador de pressão submarino
EP2405749A4 (en) THERAPY TO LOW FREQUENCY GLATIRAMERATE ACETATE
EA201390074A1 (ru) 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
BR112013025755A2 (pt) aparelho de guincho
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
EP2474262A4 (en) STEREOSCOPIC ENDOSCOPE
UA111475C2 (uk) Способи лікування із застосуванням ліпідних сполук
CL2009001973S1 (es) Mostrador.
BR112013008116A2 (pt) cabeça de poço submarino.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
ES2530436T3 (es) Combinación
FR2959346B1 (fr) Ventouse electromagnetique comportant une source lumineuse